David Young, the President of Research & Development at Processa Pharmaceuticals , Inc. (NASDAQ:PCSA), has increased his stake in the company with a recent purchase of common stock. According to a ...

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) filed a Form 8-K with the United States Securities and Exchange Commission (SEC). In this filing, Processa Pharmaceuticals disclosed that a copy of a slide ...

Processa Pharmaceuticals Inc. (PCSA) stock has tumbled to a 52-week low, touching down at $0.65, with InvestingPro data showing concerning financial health indicators and a weak overall score of 1.55.

The gross proceeds from the offering, before deducting placement agent fees and other offering expenses payable by the Company, were $5 million (excluding any proceeds that may be received upon the ...

HANOVER, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next ...

Processa Pharmaceuticals, Inc. announced the pricing of a public offering aimed at raising approximately $5 million, with participation from its CEO, board members, and institutional investors.

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA – Get Free Report)’s share price dropped 0.6% on Thursday .The stock traded as low as $0.80 and last traded at $0.87. Approximately 82,238 shares ...

The gross proceeds from the offering, before deducting placement agent fees and other offering expenses payable by the Company, are expected to be $5 million (excluding any proceeds that may be ...

Processa Pharmaceuticals, Inc. announced its participation in the 2025 BIO CEO & Investor Conference taking place on February 10-11, 2025, in New York City. The company's management will present a ...

Processa Pharmaceuticals, Inc. HANOVER, MD, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical ...

HANOVER, Md, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical ...